Meribank Biotech Co., Ltd (TPEX:4724)

Market Cap	957.84M -38.5%
Revenue (ttm)	471.76M +28.7%
Net Income	-81.47M
EPS	-0.89
Shares Out	95.98M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100,448
Open	9.99
Previous Close	10.05
Day's Range	9.55 - 10.05
52-Week Range	8.66 - 24.75
Beta	0.41
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About Meribank Biotech

Meribank Biotech Co., Ltd researches, develops, manufactures, and stores mesenchymal stem cells in Taiwan. The company engages in the detection, extraction, cryopreservation, archiving, and storage of umbilical cord blood, placental and umbilical cord mesenchymal stem cells, adult peripheral blood stem cells, and immune cells. It also provides cell cryopreservation services. The company was founded in 2001 and is based in Taipei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 142
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4724

Financial Performance

In 2025, Meribank Biotech's revenue was 471.76 million, an increase of 28.75% compared to the previous year's 366.43 million. Losses were -81.47 million, -13.99% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 14, 2026

Data Sources Report a data error